

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 January 2023 (05.01.2023)



(10) International Publication Number
WO 2023/279107 A1

(51) International Patent Classification:

A61K 39/00 (2006.01) *C07K 14/705* (2006.01)
A61K 47/68 (2017.01) *A61K 38/00* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2022/073387

(22) International Filing Date:

01 July 2022 (01.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/217,630 01 July 2021 (01.07.2021) US

(71) Applicant: **ALBERT EINSTEIN COLLEGE OF MEDICINE** [US/US]; 1300 Morris Park Avenue, Bronx, New York 10461 (US).

(72) Inventors: **ZANG, Xingxing**; 1300 Morris Park Avenue, Bronx, New York 10461 (US). **WANG, Hao**; 1300 Morris Park Avenue, Bronx, New York 10461 (US). **SICA, Rober-**


to Alejandro; 1300 Morris Park Avenue, Bronx, New York 10461 (US).

(74) Agent: **DUEPPEN, Lara** et al.; Perkins Coie LLP, P.O. Box 1247, Seattle, Washington 98111-1247 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF TMIGD2



HEL: erythroleukemia
K562: chronic myelogenous leukemia (CML)
K562a: acute myelogenous leukemia

FIG. 1A

(57) Abstract: Methods of treating cancer by inhibiting TMIGD2 expression and/or activity are provided herein. In some embodiments, the methods comprise administering one or more of: (a) a TMIGD2 mRNA targeting agent, (b) a gene-based therapeutic agent, (c) a small molecule TMIGD2 inhibitory molecule, or (d) a TMIGD2 antibody or antigen-binding fragment thereof to inhibit TMIGD2 expression and/or activity in a subject in need thereof.

[Continued on next page]

WO 2023/279107 A1

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*